Johnson & Johnson

Yahoo Finance • 4 hours ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent responses observed across atypical EGFR mutation subgroups, including th... Full story

Yahoo Finance • 8 hours ago

VYM Climbs 26% In a Year While Its Core Dividend Payers Extend Their Streaks

Quick Read The fund’s income stream relies heavily on five mature cash generators: Johnson & Johnson, Procter & Gamble, Coca-Cola, Exxon Mobil, and AbbVie. VYM’s distribution is durable for retirees, with four anchor holdings having fortr... Full story

Yahoo Finance • 10 hours ago

New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma

Johnson & Johnson EMEA MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of Johnson & Johnson’s TECVAYLI® as early as second line1 TECVAYLI®delivered deep and durable responses, with nearly two-thirds of patient... Full story

Yahoo Finance • 10 hours ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

Building on the recent approval of Johnson & Johnson's TECVAYLI® plus DARZALEX FASPRO®, MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI® as early as second line TECVAYLI® delivered deep and durable re... Full story

Yahoo Finance • 2 days ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

NEW BRUNSWICK, N.J., May 27, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15thto review second-quarter results. Joaquin Duato, Chairman and Ch... Full story

Yahoo Finance • 2 days ago

PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem

The VanEck Pharmaceutical ETF(NASDAQ:PPH) provides targeted exposure to drug manufacturers, while the iShares Global Healthcare ETF(NYSEMKT:IXJ) offers a broader reach across the international medical industry including biotechnology and e... Full story

Yahoo Finance • 3 days ago

NANOBIOTIX Announces Closing of Global Offering

PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment... Full story

Yahoo Finance • 3 days ago

NANOBIOTIX annonce le règlement-livraison de son offre globale

PARIS and CAMBRIDGE, Mass., 26 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe des approches th... Full story

Yahoo Finance • 3 days ago

President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?

Key Points Trump is looking to lower prescription drug prices in ways that could harm the profits of drugmakers in the U.S. Even if that happens, diversified healthcare players, like Johnson & Johnson and Roche, should perform just fine.1... Full story

Yahoo Finance • 3 days ago

VYM vs. VYMI: Which Vanguard Dividend ETF Is a Better Buy?

Dividend stocks can be a good choice for a few situations and investment strategies. If you're feeling nervous about high valuations of tech stocks, want to diversify into other parts of the market after recent run-ups in share prices, or... Full story

Yahoo Finance • 3 days ago

Assessing Johnson & Johnson (JNJ) Valuation After Guidance Raise Growth Initiatives And Talc Litigation Update

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Johnson & Johnson (JNJ) is in focus after a Minnesota jury include... Full story

Yahoo Finance • 3 days ago

Dow Gives Back Early Gains. Healthcare Stocks Are a Drag.

The Dow gave back its opening gains, with healthcare stocks a big drag. The blue-chip index was trading flat, while the S&P 500 was up 0.9%, and the Nasdaq rose 1.4%. UnitedHealth Group and Amgen, among the Dow's top five stocks, were down... Full story

Yahoo Finance • 4 days ago

Johnson And Johnson Innovation Hub Deal And What It Means For Valuation

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Johnson & Johnson (NYSE:JNJ) has secured naming rights for the Joh... Full story

Yahoo Finance • 4 days ago

What a $1 Million Dividend Portfolio Actually Pays After Federal AND State Taxes in California

Quick Read Conservative dividend stocks like Johnson & Johnson (NYSE:JNJ), Procter & Gamble (NYSE:PG), Coca-Cola (NYSE:KO), and the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) prioritize lower current yield but stronger long-term inco... Full story

Yahoo Finance • 4 days ago

VIG Investors: Watch the 10-Year Treasury Yield This Week—4.75% Is the Danger Line

Quick Read VIG faces structural headwinds: rising 10-year Treasury yields historically trigger 200-400 basis points of dividend-growth underperformance vs. S&P 500. Broadcom’s June 3 earnings drive VIG’s near-term outlook; fund heavily de... Full story

Yahoo Finance • 4 days ago

KNG’s 8.6 Percent Yield Comes From Selling Calls on Dividend Aristocrats, And It Has Lagged NOBL Since 2018

Quick Read FT Vest S&P 500 Dividend Aristocrats Target Income ETF (KNG) holds 69 Dividend Aristocrats including Johnson & Johnson (JNJ) and Procter & Gamble (PG), selling covered calls monthly to generate an 8.6% yield, but returned 93% o... Full story

Yahoo Finance • 4 days ago

Two Paths to Growth: Johnson & Johnson vs AbbVie

Quick Read Johnson & Johnson (JNJ) reported Q1 2026 revenue of $24.06 billion, beating expectations with 9.9% YoY growth driven by TREMFYA surging 68.3% and DARZALEX climbing 22.5% to $3.96 billion, while raising FY26 guidance to a midpoi... Full story

Yahoo Finance • 6 days ago

The Single Premium Immediate Annuity That Adds $3,800 a Month to a $1.2 Million Income Portfolio Without Touching a Stock

Quick Read A retiree can trade $500,000 in stocks for a Single Premium Immediate Annuity (SPIA) generating $3,800 monthly instead of relying on dividend growth alone. Johnson & Johnson (JNJ) and Procter & Gamble (PG) dividends grow over t... Full story

Yahoo Finance • 6 days ago

Johnson & Johnson (JNJ) Announces Positive Clinical Study Results for OTTAVA Robotic Surgical System

Johnson & Johnson (NYSE:JNJ) is one of the best low risk stocks to buy in 2026. On May 5, Johnson & Johnson announced positive results from the first clinical study of its investigational OTTAVA Robotic Surgical System. The findings from t... Full story

Yahoo Finance • 7 days ago

Catalyst Watch: Fedspeak ramps up post-Powell, core PCE, and box office blitz

[Business Stock Exchange Trading Concepts] Rawpixel Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDA... Full story